Figure 1 from Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability

Le résumé fourni par la source

CDA deletion greatly increases oral decitabine exposure. A, Plasma concentration–time profiles of decitabine following intravenous or oral (10 mg/kg) administration in WT mice. Oral bioavailability of decitabine in WT animals is markedly reduced compared with intravenous dosing. B, Plasma concentration–time profiles of decitabine following oral administration (10 mg/kg) in WT vs. CDA-KO mice. Genetic deletion of CDA resulted in an increase in oral decitabine exposure compared with WT controls, consistent with CDA-mediated presystemic metabolism limiting oral bioavailability. A and B were generated from independent WT mouse cohorts conducted at different times; therefore, variability differs despite identical decitabine dosing conditions. Data are presented as mean ± SEM (n = 5 mice per group).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.